Pharma BD Deal Intelligence
Endo's $2.6B Auxilium buy delivered Xiaflex as a lasting specialty franchise—generating $400-500M+ in annual sales through 2023—but Endo wrote off roughly 21% of the deal's value within a year on the Testim/Stendra/Natesto assets, and the parent filed Chapter 11 in 2022.
Xiaflex became a genuine specialty-pharma anchor, but Endo wrote off roughly a fifth of the purchase price within months and the parent company went bankrupt seven years later.
Full analysis, sources & comparables →Leerink's Jason Gerberry highlighted Xiaflex's Peyronie's launch as the key growth catalyst, calling the offered premium a sound exit for Auxilium holders…
Auxilium initially called Endo's $28.10 offer 'significantly undervalued' but signaled willingness to negotiate, foreshadowing the eventual $33.25 close.
Auxilium walked away from its QLT inversion in favor of Endo's $2.6B all-cash-and-stock offer at $33.25/share, a meaningful premium over Endo's initial…
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
Endo agreed to acquire specialty biopharma Auxilium Pharmaceuticals for $33.25 per share (cash-and-stock) in a deal valued at $2.6B including assumed debt. Auxilium simultaneously terminated its earlier QLT reverse-merger agreement, paying QLT a $28.4M break fee. Closed January 29, 2015.
Xiaflex became a genuine specialty-pharma anchor, but Endo wrote off roughly a fifth of the purchase price within months and the parent company went bankrupt seven years later.
Assessment window: 10yr post-close.
Peyronie's disease is a fibrotic disorder of the penile tunica albuginea causing curvature, plaque formation, pain, and erectile dysfunction. It affects men of all ages but peaks in the 55-64 cohort and is widely under-diagnosed due to patient embarrassment, leaving significant market headroom for non-surgical therapies.
Xiaflex (collagenase clostridium histolyticum) was the first and only FDA-approved non-surgical therapy for Peyronie's disease at the time of the Endo-Auxilium deal, approved in December 2013 for men with palpable plaque and curvature deformity ≥30°. Competing options were limited to surgery (plaque incision/grafting, plication, penile prosthesis), oral therapies with weak evidence (pentoxifylline, vitamin E, colchicine), and intralesional verapamil/interferon used off-label. For Dupuytren's contracture, Xiaflex competed with limited fasciectomy surgery and needle aponeurotomy. Leerink's Jason Gerberry framed the deal thesis around Xiaflex's first-line position versus surgery in Peyronie's, where diagnosis rates remained low — implying multi-year volume runway as urologist awareness builds. GlobalData's Adam Dion valued Xiaflex at $920M NPV as the centerpiece of Auxilium's ~$2.5B pharma asset base. The acquisition bolted Xiaflex, Testopel (testosterone pellets), and Stendra (avanafil PDE-5 inhibitor) onto Endo's branded men's health franchise, creating a urology specialty platform alongside Endo's existing pain and urology branded products.
Dupuytren's contracture is a progressive fibroproliferative disorder of the palmar fascia that produces nodules, cords, and finger flexion contractures, predominantly affecting men of Northern European descent over age 50. Functional impairment of the hand drives demand for both surgical and pharmacologic intervention.
In Dupuytren's, Xiaflex competes with limited fasciectomy (gold-standard surgery), needle aponeurotomy (percutaneous), and watchful waiting. Xiaflex's appeal is the office-based injection that breaks fibrotic cords without OR time or extended rehab. The deal valuation thesis rested on broader urologist and hand-surgeon adoption, with Endo's larger commercial footprint expected to accelerate uptake in both indications.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Endo International plc / Auxilium Pharmaceuticals, Inc. (this deal) | 2014 | $2.6B | 47 |
| Endo International plc / DAVA Pharmaceuticals, Inc. | 2014 | $600M | 25 |
| Endo International plc / Grupo Farmaceutico Somar SAPI de CV | 2014 | $270M | 18 |
| Endo International plc / Par Pharmaceutical Holdings, Inc. | 2015 | $8.1B | 15 |
| Ciba-Geigy AG / Sandoz AG | 1996 | $36.3B | 98 |
| Sanofi SA / Regeneron Pharmaceuticals, Inc. | 2007 | $1.0B | 97 |
| AbbVie Inc. / Boehringer Ingelheim GmbH | 2016 | $2.2B | 95 |
← Browse all deals · How we score deals
More: 2014 deals · Endo International plc deals · Dermatology deals